icad (ICAD) Debt-to-Equity

: 0.01 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

icad's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.19 Mil. icad's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.27 Mil. icad's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $33.42 Mil. icad's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for icad's Debt-to-Equity or its related term are showing as below:

ICAD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.11 Max: 4.44
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of icad was 4.44. The lowest was 0.00. And the median was 0.11.

ICAD's Debt-to-Equity is ranked better than
99.86% of 711 companies
in the Medical Devices & Instruments industry
Industry Median: 0.2 vs ICAD: 0.01

icad Debt-to-Equity Historical Data

The historical data trend for icad's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

icad Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

4.44

0.29

0.03

0.02

0.01

icad Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.02	0.10	0.10	0.02	0.01

Competitive Comparison

For the Medical Devices subindustry, icad's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

icad Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, icad's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where icad's Debt-to-Equity falls into.

icad Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

icad's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.188	+	0.273)	/	33.417
	=	0.01

icad's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.188	+	0.273)	/	33.417
	=	0.01

icad (NAS:ICAD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

icad Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of icad's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

icad (ICAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062

Website

https://www.icadmed.com

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

Executives

Eric Lonnqvist	officer: See Remarks	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea	officer: See Remarks	2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go	officer: Sr. VP of R&D	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno	officer: See Remarks	C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine	director	82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton	director	C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood	director	845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein	director	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter	officer: See Remarks	C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens	officer: Executive VP of Marketing	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado	officer: Interim Chief FinancialOfficer	98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel	director	15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard	director	C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831